Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/12005
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Borrell, Joan-Ramon | cat |
dc.date.accessioned | 2010-04-08T11:59:39Z | - |
dc.date.available | 2010-04-08T11:59:39Z | - |
dc.date.issued | 1997 | - |
dc.identifier.uri | http://hdl.handle.net/2445/12005 | - |
dc.description.abstract | [eng] This work carries out an empirical evaluation of the impact of the main mechanism for regulating the prices of medicines in the UK on a variety of pharmaceutical price indices. The empirical evidence shows that the overall impact of the rate of return cap appears to have been slight or even null, and in any case that the impact would differ across therapeutic areas. These empirical findings suggest that the price regulation has managed to encourage UK-based firms diversification in many therapeutic areas. | eng |
dc.description.abstract | [spa] Este trabajo lleva a cabo una evaluación empírica del impacto del principal mecanismo de regulación de los precios de los medicamentos en el Reino Unido sobre un conjunto de índices de precios farmacéuticos entre 1980 y 1994. La evidencia empírica muestra que la incidencia de la tasa de retorno máxima sobre los precios ha sido muy moderada o nula y que, en cualquier caso, el impacto difiere entre áreas terapéuticas. Estos resultados empíricos sugieren que la regulación de precios ha fomentado la diversificación de las empresas farmacéuticas radicadas en el Reino Unido en numerosas áreas terapéuticas. | spa |
dc.format.extent | 89999 bytes | - |
dc.format.extent | 32 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | eng |
dc.publisher | Universitat de Barcelona. Facultat d'Economia i Empresa | cat |
dc.relation.isformatof | Reproducció digital del document publicat a http://www.ere.ub.es/dtreball/E9721.rdf/view | cat |
dc.relation.ispartof | Documents de treball (Facultat d'Economia i Empresa. Espai de Recerca en Economia), 1997, E97/021 | cat |
dc.relation.ispartofseries | [WP E-Eco 97/021] | - |
dc.rights | cc-by-nc-nd, (c) Borrell, 1997 | - |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/es/ | - |
dc.source | UB Economics – Working Papers [ERE] | - |
dc.subject.classification | Despesa pública | cat |
dc.subject.classification | Política econòmica | cat |
dc.subject.classification | Salut pública | cat |
dc.subject.classification | Medicaments | cat |
dc.subject.classification | Preus | cat |
dc.subject.classification | Gran Bretanya | cat |
dc.subject.other | Public expenditures | eng |
dc.subject.other | Economic policy | eng |
dc.subject.other | Public health | eng |
dc.subject.other | Drugs | eng |
dc.subject.other | Pricing | eng |
dc.subject.other | Great Britain | eng |
dc.title | Prices of medicines: a case-study on the impact of the rate-of-return regulation in the United Kingdom | eng |
dc.type | info:eu-repo/semantics/workingPaper | eng |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
Appears in Collections: | UB Economics – Working Papers [ERE] Documents de treball / Informes (Econometria, Estadística i Economia Aplicada) |
This item is licensed under a Creative Commons License